Last quarter (Q4 2023), Orchestra BioMed Holdings's total revenue was $594.00K, an increase of Infinity% from the same quarter last year. In Q4, Orchestra BioMed Holdings's net income was $-38.23M. See Orchestra BioMed Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 2.76M	$ 2.76M	-	-	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 2.76M	$ 2.76M	-	-	-
Operating Expense	$ 54.27M	$ 54.27M	$ 3.08M	$ 394.76K	$ 179.99K
Operating Income	$ -51.51M	$ -51.51M	$ -3.08M	$ -394.76K	$ -179.99K
Net Non Operating Interest Income Expense	$ 3.85M	$ 3.85M	$ 345.14K	$ 16.00K	-
Other Income Expense	$ 1.47M	$ 1.47M	-	-	$ 6.44K
Pretax Income	$ -49.12M	$ -49.12M	$ -2.74M	$ -378.75K	$ -173.54K
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -49.12M	$ -49.12M	$ -2.74M	$ -378.75K	$ -173.54K
Basic EPS	$ -1.49	$ -1.48	$ -0.17	$ -0.02	$ -0.01
Diluted EPS	$ -1.49	$ -1.48	$ -0.17	$ -0.02	$ -0.01
Basic Average Shares	$ 132.90M	$ 33.23M	$ 16.43M	$ 20.45M	$ 15.79M
Diluted Average Shares	$ 132.90M	$ 33.23M	$ 16.43M	$ 20.45M	$ 15.79M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 54.27M	$ 54.27M	$ 3.08M	$ 394.76K	$ 179.99K
Net Income From Continuing And Discontinued Operation	$ -49.12M	$ -49.12M	$ -2.74M	$ -378.75K	$ -173.54K
Normalized Income	$ -50.22M	$ -38.81M	-	-	$ -179.99K
Interest Expense	-	-	-	-	-
EBIT	$ -24.34M	$ -52.97M	$ -2.74M	$ -394.76K	$ -179.99K
EBITDA	$ -25.08M	$ -55.76M	$ -2.74M	$ -394.76K	$ -179.99K

Currency in USD

Orchestra BioMed Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing